MultiLINK™ ADC Technology Suite
The MultiLINK™ ADC Technology Suite is a modular platform of tunable, peptide-based, cathepsin B-cleavable linkers combined with advanced conjugation technologies, built to support rational ADC design rather than one-size-fits-all solutions.
The suite allows you to move beyond “plug-and-play” linkers, enabling a “Trifecta” ADC development approach. It includes deliberate, program-specific selection of the right linker based on the unique combination of antibody, payload, and clinical context, because clinical success depends on achieving the optimal balance across these three elements.
In short
Moving beyond "one-size-fits-all" linkers, the MultiLINK™ Technology Suite offer a range of modular and tunable peptide-based linkers.
A versatile range of adaptable ADC linker and conjugation solutions enabling the development of optimized ADCs with truly superior therapeutic performance.
Focus on our "Trifecta Approach"
MultiLINK™ is a critical enabler of Debipharm’s “Trifecta Approach” for developing optimized, fit-for-purpose ADCs that meet specific therapeutic objectives.
This approach is based on strategic selection of targeted antibodies, selection of the right linker from our range of proprietary MultiLINK™ linkers, and smart payload choices. The impact of choosing the right linker is often the most underestimated out of all the ADC components. The linker is more than a connector, it is a key driver of the therapeutic effect. For an optimised fit-for purpose ADC, linker selection must be driven by multiple factors like antibody and payload selection, disease properties and patient population characteristics. Our MultiLINKTM Technology Suite consists of a range of linker and linker payload options, providing the flexibility to select the right linker for any given clinical context.
MultiLINK™ Technology Suite Highlights
- Optimized stability: PK parameters comparable to naked antibodies
- High DAR and hydrophobicity mitigation capabilities: Enabling delivery of high Drug-to-Antibody Ratios (up to DAR 16) without compromising stability or inducing aggregation
- Dual Payload innovation: First-in-class capability to deliver two different payloads (up to DAR 8+8) on a single antibody to tackle tumor heterogeneity and drug resistance
- Rapid POC generation enabling fast-track proof-of-concept testing: Conjugation of first batches can be achieved in as little as just 3 weeks
Debiopharm’s ADC Portfolio
Our ADC portfolio consists of strategically selected targets with 1st-in-class or best-in-class potential, combined with proprietary MultiLINK™ technology and smart payload choices. Our lead program, Debio 1562M, a CD37-targeted ADC is currently in Phase 1/2 for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Our pipeline leverages next‑generation ADC modalities, including dual‑payload and bispecific.
We tailor collaborations to
- Accelerate your ADC program: Solve complex linker challenges by integrating MultiLINK™ technology into your ADC development.
- Realize your antibody’s potential: We in-license your antibody and integrate it with MultiLINK™ technology into our ADC pipeline.
- Expand your ADC portfolio: Gain access to high-potential ADC assets through out-licensing opportunities from our internal pipeline.
Our Ongoing Partnerships
Clinical trials
MultiLINK™. Modular. Tunable. Peptide-Based.
MultiLINK™ provides a comprehensive toolbox of options allowing ADCs to be optimized for specific clinical contexts.
By focusing on the often-underestimated role of the linker, we unlock the full potential of both antibody and payload based on their specific physiochemical properties and the disease biology.
